Paolo Fabbri
Overview
Explore the profile of Paolo Fabbri including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
93
Citations
727
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Torresan F, Piccinini L, Cacace M, Pola M, Zampieri D, Fabbri P
Environ Geochem Health
. 2021 Jul;
44(7):2135-2162.
PMID: 34269957
Renewable natural resources are strategic for reducing greenhouse gas emissions and the human footprint. The renewability of these resources is a crucial aspect that should be evaluated in utilization of...
2.
Antiga E, Maglie R, Fabbri P
J Invest Dermatol
. 2020 Dec;
141(6):1585.
PMID: 33307102
No abstract available.
3.
Maglie R, Quintarelli L, Verdelli A, Fabbri P, Antiga E, Caproni M
G Ital Dermatol Venereol
. 2018 Oct;
154(3):286-298.
PMID: 30375214
Specific dermatoses of pregnancy are skin disorders that occur specifically during or immediately after pregnancy and cannot be found in non-pregnant patients. According to the current consensus, they include atopic...
4.
Dalla Libera N, Fabbri P, Mason L, Piccinini L, Pola M
Sci Total Environ
. 2017 Apr;
598:330-340.
PMID: 28448925
The Natural Background Level (NBL), suggested by UE BRIDGE project, is suited for spatially distributed datasets providing a regional value that could be higher than the Threshold Value (TV) set...
5.
Conteduca V, Crabb S, Jones R, Caffo O, Elliott T, Scarpi E, et al.
PLoS One
. 2016 Jul;
11(7):e0158952.
PMID: 27434372
The baseline value of neutrophil to lymphocyte ratio (NLR) has been found to be prognostic in patients with metastatic castration resistant prostate cancer (CRPC). We evaluated the impact of baseline...
6.
Conteduca V, Crabb S, Scarpi E, Hanna C, Maines F, Joyce H, et al.
Mol Diagn Ther
. 2016 Mar;
20(3):255-63.
PMID: 27020582
Objective: Prostate-specific antigen (PSA) decline by 50 % from the baseline to 12 weeks (PSA50w12) is currently used to predict response to treatment and clinical outcome of patients with metastatic...
7.
De Angelis D, Gibelli D, Fabbri P, Cattaneo C
Am J Forensic Med Pathol
. 2015 Jun;
36(3):219-20.
PMID: 26079404
Age estimation involves the reconstruction of age by biological parameters such as skeletal and dental development in minors, or reduction of pulp chamber in adults, to gain indications concerning the...
8.
Prignano F, Tripo L, Amato L, Bagnoni G, Bartoli L, Battistini S, et al.
G Ital Dermatol Venereol
. 2015 Jan;
152(2):99-108.
PMID: 25588061
Background: Psoriasis is traditionally defined as an inflammatory chronic-relapsing disease of the skin. As widely demonstrated, this disease is also associated with multiple comorbidities: arthropathy, inflammatory bowel disease, metabolic, cardiovascular,...
9.
Antiga E, Quaglino P, Pierini I, Volpi W, Lami G, Bianchi B, et al.
J Dermatol Sci
. 2014 Dec;
77(1):54-62.
PMID: 25465638
Background: Dermatitis herpetiformis (DH) and celiac disease (CD) are considered as autoimmune diseases that share a defined trigger (gluten) and a common genetic background (HLA-DQ2/DQ8). However, the pathogenesis of DH...
10.
Burgio S, Conteduca V, Rudnas B, Carrozza F, Campadelli E, Bianchi E, et al.
Clin Genitourin Cancer
. 2014 Jul;
13(1):39-43.
PMID: 24999168
Background: The aim of this study was to assess early serum prostate-specific antigen (PSA) changes in patients treated with abiraterone and to correlate those changes with clinical outcome. Patients And...